BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu L, Yang X, Huang N, Lang QL, He QL, Jian-Hua W, Liang-Peng G. A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma. Cancer Biol Ther. 2020;21:597-603. [PMID: 32240054 DOI: 10.1080/15384047.2020.1743158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Ordóñez-Reyes C, Garcia-Robledo JE, Chamorro DF, Mosquera A, Sussmann L, Ruiz-Patiño A, Arrieta O, Zatarain-Barrón L, Rojas L, Russo A, de Miguel-Perez D, Rolfo C, Cardona AF. Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question. Pharmaceutics 2022;14:1243. [PMID: 35745815 DOI: 10.3390/pharmaceutics14061243] [Reference Citation Analysis]
2 Deng H, Niu Z, Zhang Z, Zhang J, Wang G, Wang Y, Yang J. Back on the scene: advances and challenges in CD3-related drugs in tumor therapy. Drug Discov Today 2022:S1359-6446(22)00169-6. [PMID: 35489674 DOI: 10.1016/j.drudis.2022.04.019] [Reference Citation Analysis]
3 Tan X, Yang J, Jiang J, Wang W, Ren J, Li Q, Xie Z, Chen X, Zhang L, Li W. Significant Growth Inhibition by a Bispecific Affibody Targeting Oncoprotein E7 in both HPV16 and 18 Positive Cervical Cancer in vitro and in vivo. Eur J Pharm Sci 2022;:106156. [PMID: 35245683 DOI: 10.1016/j.ejps.2022.106156] [Reference Citation Analysis]
4 Wang K, Wang C, Jiang H, Zhang Y, Lin W, Mo J, Jin C. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. Front Immunol 2021;12:792781. [PMID: 34975896 DOI: 10.3389/fimmu.2021.792781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wu Y, Yi M, Zhu S, Wang H, Wu K. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol 2021;10:56. [PMID: 34922633 DOI: 10.1186/s40164-021-00250-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Yu L, Huang N, Ge L, Sun H, Fu Y, Liu C, Wang J. Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds. J Biol Eng 2021;15:18. [PMID: 34187511 DOI: 10.1186/s13036-021-00272-7] [Reference Citation Analysis]
7 Yu L, Huang N, Sun H, Yang X, Fu Y, Lang Q, Wang J, Ge L. Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma. J Immunother 2021;44:106-13. [PMID: 33239522 DOI: 10.1097/CJI.0000000000000349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Du K, Li Y, Liu J, Chen W, Wei Z, Luo Y, Liu H, Qi Y, Wang F, Sui J. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Mol Ther 2021;29:1572-84. [PMID: 33429083 DOI: 10.1016/j.ymthe.2021.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
9 Vaziri F, Colquhoun S, Wan YY. Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. Liver Res 2020;4:191-8. [PMID: 33343967 DOI: 10.1016/j.livres.2020.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Guo Z, Wang J, Li L, Liu R, Fang J, Tie B. Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. World J Clin Cases 2020; 8(16): 3493-3502 [PMID: 32913856 DOI: 10.12998/wjcc.v8.i16.3493] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]